Imiquimod

Imiquimod
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Deepika Beereddy, MBBS [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Imiquimod is an immnunologic adjuvant that is FDA approved for the treatment of actinic keratosis, external genital warts. Common adverse reactions include erythema, edema, erosion/ulceration, exudate, scabbing/crusting, headache, application site pain, application site irritation, application site pruritus, fatigue, influenza-like illness, and nausea.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Actinic Keratosis

• ZYCLARA Cream, 2.5% and 3.75% are indicated for the topical treatment of clinically typical visible or palpable, actinic keratoses (AK), of the full face or balding scalp in immunocompetent adults.

• Dosing Information

• ZYCLARA Cream should be applied once daily before bedtime to the skin of the affected area (either entire face or balding scalp) for two 2-week treatment cycles separated by a 2-week no-treatment period. ZYCLARA Cream should be applied as a thin film to the entire treatment area and rubbed in until the cream is no longer visible. Up to 0.5 grams (2 packets or 2 full actuations of the pump) of ZYCLARA Cream may be applied to the treatment area at each application. ZYCLARA Cream should be left on the skin for approximately 8 hours, after which time the cream should be removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ZYCLARA Cream therapy.

• Patients should wash their hands before and after applying ZYCLARA Cream.

• Avoid use in or on the lips and nostrils. Do not use in or near the eyes.

• Local skin reactions in the treatment area are common [see Adverse Reactions (6.1)]. A rest period of several days may be taken if required by the patient's discomfort or severity of the local skin reaction. However, neither 2-week treatment cycle should be extended due to missed doses or rest periods. A transient increase in lesion counts may be observed during treatment. Response to treatment cannot be adequately assessed until resolution of local skin reactions. The patient should continue dosing as prescribed. Treatment should continue for the full treatment course even if all actinic keratoses appear to be gone. Lesions that do not respond to treatment should be carefully re-evaluated and management reconsidered.

• Prescribe no more than 2 boxes (56 packets), two 7.5g pumps or one 15g pump for the total 2-cycle treatment course. Partially-used packets should be discarded and not reused.

External Genital Warts

• ZYCLARA Cream, 3.75% is indicated for the treatment of external genital and perianal warts (EGW)/condyloma acuminata in patients 12 years or older.

• Dosing Information

• Patients should apply a thin layer of ZYCLARA Cream once a day to the external genital/perianal warts until total clearance or for up to 8 weeks. Patients should use up to 0.25 grams (one packet or one full actuation of the pump) at each application, which is a sufficient amount of cream to cover the wart area. ZYCLARA Cream should be applied prior to normal sleeping hours and left on the skin for approximately 8 hours, then removed by washing the area with mild soap and water. The prescriber should demonstrate the proper application technique to maximize the benefit of ZYCLARA Cream therapy.

• Patients should wash their hands before and after applying ZYCLARA Cream.

• Local skin reactions at the treatment site are common, and may necessitate a rest period of several days; resume treatment once the reaction subsides. Non-occlusive dressings such as cotton gauze or cotton underwear may be used in the management of skin reactions.

• Prescribe up to 2 boxes (56 packets), two 7.5g pumps or one 15g pump for the total treatment course. Use of excessive amounts of cream should be avoided. Partially-used packets should be discarded and not reused.

Superficial basal cell carcinoma, on trunk, neck, or extremities; when surgical methods are less appropriate and follow-up is assured

• Dosing Information

• Tumors 0.5 cm to less than 1 cm in diameter, apply a 4 mm diameter cream droplet (10 mg); tumors 1 cm to less than 1.5 cm in diameter, apply a 5 mm diameter cream droplet (25 mg); tumors 1.5 cm to 2 cm in diameter, apply a 7 mm cream droplet (40 mg of cream)

Limitations of Use

• Imiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy.

• Treatment with ZYCLARA Cream has not been studied for prevention or transmission of HPV.

Unevaluated Populations

• The safety and efficacy of ZYCLARA Cream have not been established in the treatment of:

• urethral, intra-vaginal, cervical, rectal or intra-anal human papilloma viral disease.
• actinic keratosis when treated with more than one 2-cycle treatment course in the same area.
• patients with xeroderma pigmentosum.
• superficial basal cell carcinoma.
• immunosuppressed patients.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Imiquimod in adult patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Imiquimod in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding FDA-Labeled Use of Imiquimod in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Condition1

• Developed by:

• Class of Recommendation:

• Strength of Evidence:

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Guideline-Supported Use of Imiquimod in pediatric patients.

Non–Guideline-Supported Use

Condition1

• Dosing Information

• Dosage

Condition2

There is limited information regarding Off-Label Non–Guideline-Supported Use of Imiquimod in pediatric patients.

Contraindications

• Condition1

Warnings

• Description

Precautions

• Description

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Imiquimod in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Imiquimod in the drug label.

Body as a Whole

Cardiovascular

Digestive

Endocrine

Hematologic and Lymphatic

Metabolic and Nutritional

Musculoskeletal

Neurologic

Respiratory

Skin and Hypersensitivy Reactions

Special Senses

Urogenital

Miscellaneous

Drug Interactions

• Drug

• Description

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

• Pregnancy Category

Pregnancy Category (AUS):

• Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Imiquimod in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Imiquimod during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Imiquimod with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Imiquimod with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Imiquimod with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Imiquimod with respect to specific gender populations.

Race

There is no FDA guidance on the use of Imiquimod with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Imiquimod in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Imiquimod in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Imiquimod in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Imiquimod in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

• Intravenous

Monitoring

There is limited information regarding Monitoring of Imiquimod in the drug label.

• Description

IV Compatibility

There is limited information regarding IV Compatibility of Imiquimod in the drug label.

Overdosage

Acute Overdose

Signs and Symptoms

• Description

Management

• Description

Chronic Overdose

There is limited information regarding Chronic Overdose of Imiquimod in the drug label.

Pharmacology

There is limited information regarding Imiquimod Pharmacology in the drug label.

Mechanism of Action

Structure

File:Imiquimod01.png

This image is provided by the National Library of Medicine.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Imiquimod in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Imiquimod in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Imiquimod in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Imiquimod in the drug label.

How Supplied

Storage

There is limited information regarding Imiquimod Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Imiquimod |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Imiquimod |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Imiquimod in the drug label.

Precautions with Alcohol

• Alcohol-Imiquimod interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• ®

Look-Alike Drug Names

• A® — B®

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Imiquimod
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Imiquimod
 |Label Name=Imiquimod11.png

}}

{{#subobject:

 |Label Page=Imiquimod
 |Label Name=Imiquimod11.png

}}